

# Innovus Pharma


## CORPORATE PROFILE

Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

9171 Towne Centre Drive, Ste 440 IR@InnovusPharma.com  
San Diego, CA 92122 T: (858) 964-5123  
Phone: (858) 964-5123  
Fax: (858) 249-7879  
<http://www.innovuspharma.com>  
[info@innovuspharma.com](mailto:info@innovuspharma.com)

## STOCK PERFORMANCE

Symbol	INNV
Exchange	OTCQB
Market Cap.	14.64m
52 Week Range	0.082 - 0.39
Close	0.0999
Volume	677
Shares Outstanding	151,303,679
As of Sep 22, 2017 3:59 pm	



## MANAGEMENT TEAM

**Bassam Damaj, Ph.D.** - President and Chief Executive Officer

**Randy Berholtz, MBA/JD** - Executive Vice President, Corporate Development and General Counsel

**Rauly Gutierrez, CPA** - Vice President, Finance and Principal Financial and Accounting Officer

## RECENT HEADLINES

[Sep 20, 2017 - Innovus Pharma's Partner Luminarie Receives Approval for Zestra® for Female Sexual Arousal Disorder as a Medical Device I from New Zealand's Medicines and Medical Devices Safety Authority](#)

[Sep 19, 2017 - Innovus Pharma Announces the Launch of Zestra® in France, Belgium and Monaco by Its Partner, Densmore](#)

[Sep 6, 2017 - Innovus Pharma Receives Approval from Health Canada for its UriVarx\(TM\) Product for the Indication to Reduce Symptoms of Overactive Bladder such as Daytime Urinary Frequency, Urgency and Nocturia](#)

[Aug 28, 2017 - Innovus Pharma to Present at Rodman & Renshaw 19th Annual Global Investment Conference](#)

[Aug 24, 2017 - Innovus Pharma Files Product License Application for the Commercialization of Its Seasonal Allergic Rhinitis Product in Canada](#)

## PAST EVENTS

Apr 30, 2016 - The San Diego Union Tribune Successful Aging Expo